Drawing for BIOCARESD

USPTO serial 88168007

BIOCARESD

Reviewed by CopyMark Law Group

Reg. 5853298Status 702Registered
Filing date
Status date
Registration date
Sep 3, 2019
Examiner
JOHNSON, BRITTANY S
Law office
Historical data usage

What this means

Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use. Continue use in commerce and plan for the 10-year Section 8 and 9 renewal.

Status 702: Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use.

Need help with BIOCARESD?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Emily A. Bayton

Emily A. Bayton FAEGRE DRINKER BIDDLE & REATH LLP1144 15th Street, Suite 3400Denver, CO 80202United States

Goods and services

ClassDescriptionStatusFirst use
035Consignment inventory services, namely, inventory management in the field of biologic and specialty pharmaceutical products in the nature of therapeutic plasma-derivatives and recombinant coagulation products provided to hospitals, clinics, home care companies, hemophilia and thrombosis centers, and physician officesACTIVEApr 29, 2019
039Distribution services, namely, delivery of therapeutic plasma-derivatives and recombinant coagulation products used for hemophilia and thrombophilia treatment, immunology, wound management, and critical care; biopharmaceutical and specialty pharmaceutical distribution services, namely, transport, delivery, packaging and storage of therapeutic plasma-derivatives and recombinant coagulation products for hospitals, clinics, home care companies, hemophilia and thrombosis centers, and physician officesACTIVEApr 29, 2019

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
May 3, 2025NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
May 3, 2025C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
May 3, 2025APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Jan 15, 2025E815TEAS SECTION 8 & 15 RECEIVED—
Sep 3, 2024REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Sep 3, 2019R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Aug 2, 2019SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Aug 1, 2019CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Jul 17, 2019SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Jul 17, 2019AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Jun 25, 2019IUAFUSE AMENDMENT FILED—
Jun 25, 2019EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Jun 11, 2019ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 11, 2019REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
May 14, 2019NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Mar 19, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 19, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 27, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Feb 6, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 31, 2019DOCKASSIGNED TO EXAMINER—
Nov 7, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 27, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance